Devyser Diagnostics AB
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovaria… Read more
Devyser Diagnostics AB (DVYSR) - Total Assets
Latest total assets as of September 2025: Skr459.90 Million SEK
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) holds total assets worth Skr459.90 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Devyser Diagnostics AB - Total Assets Trend (2018–2024)
This chart illustrates how Devyser Diagnostics AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Devyser Diagnostics AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Devyser Diagnostics AB's total assets of Skr459.90 Million consist of 53.3% current assets and 46.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 30.5% |
| Accounts Receivable | Skr74.60 Million | 15.8% |
| Inventory | Skr30.20 Million | 6.4% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr95.00 Million | 20.1% |
| Goodwill | Skr7.00 Million | 1.5% |
Asset Composition Trend (2018–2024)
This chart illustrates how Devyser Diagnostics AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Devyser Diagnostics AB's current assets represent 53.3% of total assets in 2024, a decrease from 57.7% in 2018.
- Cash Position: Cash and equivalents constituted 30.5% of total assets in 2024, up from 15.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 20.1% of total assets.
Devyser Diagnostics AB Competitors by Total Assets
Key competitors of Devyser Diagnostics AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Devyser Diagnostics AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Devyser Diagnostics AB generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Devyser Diagnostics AB is currently not profitable relative to its asset base.
Devyser Diagnostics AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.78 | 4.21 | 14.02 |
| Quick Ratio | 2.27 | 3.81 | 13.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr131.70 Million | Skr 197.40 Million | Skr 383.23 Million |
Devyser Diagnostics AB - Advanced Valuation Insights
This section examines the relationship between Devyser Diagnostics AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.82 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | Skr473.80 Million |
| Market Capitalization | $80.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Devyser Diagnostics AB's assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Devyser Diagnostics AB's assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Devyser Diagnostics AB (2018–2024)
The table below shows the annual total assets of Devyser Diagnostics AB from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr473.80 Million | -7.12% |
| 2023-12-31 | Skr510.10 Million | +1.89% |
| 2022-12-31 | Skr500.63 Million | +9.58% |
| 2021-12-31 | Skr456.87 Million | +514.43% |
| 2020-12-31 | Skr74.36 Million | +0.89% |
| 2019-12-31 | Skr73.70 Million | +52.84% |
| 2018-12-31 | Skr48.22 Million | -- |